Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
Source: View publication →
Maternal vaccination with the bivalent RSVpreF vaccine significantly reduced the incidence of severe RSV-associated lower respiratory tract illness in infants during the first 6 months of life.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial supports the use of maternal RSV vaccination as a highly effective strategy to protect infants from severe RSV-associated morbidity during the most vulnerable early months of life.
Historical Context
RSV has long been a leading cause of infant hospitalization globally without targeted prophylactic options for newborns, historically relying on passive immunization with monoclonal antibodies like palivizumab for high-risk infants; the MATISSE trial provided the pivotal phase 3 evidence for maternal vaccination to provide active immunity via transplacental transfer.
Guided Discussion
High-yield insights from every perspective
Maternal immunization with RSVpreF relies on the transplacental transfer of antibodies. What specific class of immunoglobulins is transferred, and why is the 'prefusion' state of the F protein specifically targeted for vaccine development?
Key Response
Maternal IgG is actively transported across the placenta via the neonatal Fc receptor (FcRn). The RSV fusion (F) protein is the primary target for neutralizing antibodies; however, it is highly unstable. The prefusion conformation (preF) displays several potent, highly neutralizing epitopes (such as Site Ø) that are lost once the protein triggers into the postfusion state. Targeting the preF state induces a much more potent neutralizing antibody response than targeting the postfusion state.
In the MATISSE trial, maternal RSVpreF vaccination demonstrated high efficacy against 'severe' RSV-associated lower respiratory tract illness (MA-LRT). How should this influence the clinical management and parental counseling for an infant born to a vaccinated mother who presents with mild upper respiratory symptoms?
Key Response
The trial showed approximately 81.8% efficacy against severe MA-LRT within 90 days but lower efficacy (51.3%) against any medically attended RSV-LRT. Residents should counsel parents that while the vaccine is highly effective at preventing ICU-level illness and hypoxia, it does not completely eliminate the risk of mild to moderate RSV infection. Clinical monitoring for work of breathing and hydration remains essential regardless of maternal vaccination status.
The MATISSE trial enrolled participants between 24 and 36 weeks of gestation. When integrating these findings with the subsequent FDA approval and ACIP recommendations, why was the administration window narrowed to 32-36 weeks in clinical practice guidelines?
Key Response
While MATISSE allowed vaccination starting at 24 weeks, a concurrent trial of a similar RSV vaccine (GSK) was halted due to a signal for increased preterm births. Although MATISSE did not show a statistically significant increase in preterm birth (5.7% vaccine vs 4.7% placebo), the FDA and ACIP adopted a 32-36 week window as a precautionary measure to minimize the risk of vaccine-associated preterm delivery while still allowing sufficient time for placental antibody transfer.
How do the results of the MATISSE trial complicate the implementation of neonatal prophylaxis with nirsevimab in a high-volume obstetric and pediatric setting?
Key Response
The availability of both maternal vaccination (active immunity) and nirsevimab (passive immunity) creates a 'one or the other' scenario in most clinical guidelines (e.g., CDC). Attendings must lead the implementation of systems to ensure clear communication between the obstetric record and the pediatric record to avoid redundant administration, while also identifying niche cases (e.g., infants born <14 days after maternal vaccination) where both might be indicated due to insufficient antibody transfer time.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MATISSE trial used a Bayesian design with a success criterion defined by the lower bound of the 95.02% credible interval for vaccine efficacy exceeding 20%. What are the methodological advantages and risks of using this Bayesian approach over traditional frequentist p-value thresholds in a phase 3 vaccine trial?
Key Response
The Bayesian approach allows for the incorporation of prior information and provides a more intuitive probability of efficacy. It allows for flexible interim analyses without the same 'multiplicity' penalties as frequentist designs. However, the risk lies in the sensitivity to the choice of the prior distribution and the potential for a 'success' definition that might not align with the stringent p<0.05 requirements typically expected for regulatory approval if the credible interval is not constructed conservatively.
As a reviewer, how would you evaluate the potential for 'healthy vaccinee bias' in the MATISSE trial, and does the 1:1 randomization adequately address the seasonal variability of RSV across the multiple global sites used in the study?
Key Response
Editors look for whether the randomization was stratified by site and timing to ensure that placebo and vaccine groups had equal exposure to RSV seasons. In MATISSE, the global multi-center design helps generalizability, but if certain sites had disproportionate enrollment during 'off-seasons,' the overall efficacy could be diluted. The use of a 1:1 randomization helps, but the editor would scrutinize the 'Per-Protocol' vs 'Intention-to-Treat' populations to ensure that dropouts or early births didn't skew the results toward the null.
Based on the MATISSE data, how should the strength of recommendation for maternal RSVpreF be graded for mothers at high risk for preterm labor, considering the current ACOG and CDC recommendations?
Key Response
Currently, ACOG and the CDC/ACIP recommend maternal RSVpreF specifically during weeks 32-36 of pregnancy to maximize safety. For patients at high risk for preterm labor (e.g., shortened cervix, prior preterm birth), the guideline committee must weigh the benefit of RSV protection against the theoretical risk of triggering delivery. Currently, the evidence is rated as a strong recommendation based on high-quality evidence (Level A) for efficacy, but with specific gestational age restrictions to mitigate safety concerns identified in the broader class of RSV prefusion vaccines.
Clinical Landscape
Noteworthy Related Trials
Nirsevimab MELODY Trial
Tested
Nirsevimab
Population
Healthy late-preterm and term infants
Comparator
Placebo
Endpoint
Incidence of medically attended RSV-associated lower respiratory tract infection
RSV MAT-009 Trial
Tested
RSVpreF maternal vaccine
Population
Pregnant women 24-36 weeks gestation
Comparator
Placebo
Endpoint
Medically attended severe RSV-associated lower respiratory tract illness in infants
GSK Maternal RSV Vaccine Trial
Tested
Unadjuvanted RSVPreF3 maternal vaccine
Population
Pregnant women 24-34 weeks gestation
Comparator
Placebo
Endpoint
Medically attended RSV-associated lower respiratory tract disease in infants
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis